Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (911)	3/17/1999 11:44:00 AM
From: bob s	Respond to of 3202

COMPETITION?? Is that a valid reason for the big drop?? How real is it?? Thanks for the input. Bob

To: Rocketman who wrote (911)	3/17/1999 1:01:00 PM
From: John Starks	Respond to of 3202

I haven't seen anybody mention the NYT article yesterday (A21) which may have balanced out the apparently pro-Venter NPR piece (i didn't catch the piece). The article in the Times reported that the NIH-led sequencing consortium announced that they would "have a first draft of the human genome in spring of 2000." This cuts 18 months off the initial prediction. Venter is quoted in the article in response stating, "It has nothing to do with reality...It is projected cost, projected timetables." The article in a nut shell suggests that Celera's bold projections added competition to the genome sequencing field and was responsible for the increased efforts of the consortium. One thing that i haven't heard mentioned in discussions about sequencing companies is Celera's pilot project: sequencing the Drosophila genome. Although at first glance one might dismiss the commercial potential of such a project, I wonder if they will end up charging researchers for access to this data base. I know that there would be significant demand in academic labs for this information and I also think companies working on oncogenic pathways that are evolutionarily conserved (many seem to be) would also be willing to pay for access. any thoughts on the commercial potential of the Drosophila genome project?

To: Rocketman who wrote (911)	3/17/1999 10:28:00 PM
From: LLCF	Read Replies (1) \| Respond to of 3202

<NPR, DNA Files and Venter et al...> AS I keep buying INCY on the way down I must say: Venter and the competition are on OUR side IMO! Why? Because the weakness in the stock is due to worry over these patents of genes holding up in the long run. Wall Street is in between pricing this thing as the greatest thing since sliced bread, and a commodity company that sells info. I Can't imagine the weakness we are seeing is due to competition being "puffed up" in the press. Comments? DAK

To: Rocketman who wrote (911)	3/18/1999 1:36:00 PM
From: John Starks	Respond to of 3202

<<<<<<<< HYSEQ AWARDED PATENT ON DEVICE FOR PRINTING PROBES ON DNA CHIPS IN A SINGLE STEP --Device May Simplify DNA Chip Production-- SUNNYVALE, CA, March 16, 1999 Hyseq, Inc. (Nasdaq: HYSQ) today announced the issuance of United States Patent No. 5,882,930, titled "Reagent Transfer Device", which covers a printing device to enhance the speed and efficiency for the production of DNA chips. "This device allows us to deposit all probes onto a chip or other surfaces in a single step, rather than in multiple steps, or in the complex 'in situ' probE synthesis process presently being used by other chip makers," said Lewis S. Gruber, President and CEO of Hyseq, Inc. "We believe this device will have significant advantages for DNA chip production," said Joerg W. Baier, Director of Engineering and Technology, HyChipTM Project Leader and the inventor of the device. "This patent demonstrates our commitment to parallel processing and high throughput improvements." Hyseq, Inc., based in Sunnyvale, California, is a biopharmaceutical company with a growing pipeline of biopharmaceutical product candidates in its proprietary HyProfile™ portfolio. Hyseq offers pharmacogenomics/polymorphism databases and believes that its fast-growing proprietary HyGenomics™ database of partial human DNA sample sequences is the worldÃÔ largest. IN gene chip technology, Hyseq, with its partner, PE Corporation (formerly known as The Perkin-Elmer Corporation) offers the only universal sequencing chip through their HyChip™ Early Access Program. Information about Hyseq is available on the World Wide Web at hyseq.com or by phoning (408) 524-8100. >>>>>>>>>>>>>>>>>>>>> ANY COMMENTS FROM THOSE IN THE KNOW ABOUT CHIP PRODUCTION? ------ Previous